Immix Biopharma Investor Presentation Deck
Broad Autoimmune Disease Applicability of the ImmixBio N-GENIUS Platform
Overcoming Neurotoxicity Enables Indication Expansion For NXC-201
CD19
CD20
●
●
●
BCMA
Myasthenia Gravis
Neuromyelitis Optica Spectrum Disorder
Pemphigus Vulgaris
Dermatomyositis
Ulcerative Colitis
Celiac disease
Bone Marrow
Pro-B
Pre-B Immature B Naïve B
Neurology
Dermatology
Gastroenterology
Periphery
I
GC B Memory B Plasma blast
I
Bone Marrowi
I
Plasma cell I
I
I
I
Rheumatology
Hematology
Nephrology
Other diseases
AL Amyloidosis, Multiple Myeloma
(3-days hospital instead of 14-days)
Overcoming neurotoxicity
●●●
S
IMMIX
BIOPHARMA
Systemic Lupus Erythematosus
Rheumatoid Arthritis
IgA nephropathy
IgM nephropathy
AL Amyloidosis
Waldenström macroglobulinemia
*Illustrative list of autoimmune diseases where B cells may play a role in initiating or maintaining disease, and where NXC-201 may provide a potential treatment
Source: Medic Tests. Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 2020. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022. Qin C, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory
AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023. Granit V, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a
study. Lancet Neurol. 2023. Shaker OG, et al. Expression of TNF-a, APRIL and BCMA in Behcet's disease. J Immunol Res. 2014. Shimanovsky A, et al. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016. McGlothlin J, et al. Bortezomib and
daratumumab in refractory autoimmune hemolytic anemia. Am J Hematol. 2023. Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA)? [published correction appears in Nephrol Dial Transplant. 2005. Yu TS, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv.
2021. Greenberg SA, et al. Plasma cells in muscle in inclusion body myositis and polymyositis [published correction appears in Neurology. 2006. Wilbrink R, et al. B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis. Int J Mol Sci. 2021. Uzzan M, et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral
response associated with disease activity. Nat Med. 2022. Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?. Front Immunol. 2023
6View entire presentation